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Summary 
Inhaled corticosteroids (ICS) are established as a cornerstone of management for patients 
with bronchoconstrictive lung disease. However, systemic absorption may lead to 
suppression of the hypothalamic-pituitary-adrenal (HPA) axis in a significant minority of 
patients. This is more likely in ‘higher risk’ patients exposed to high cumulative ICS doses, 
and in those treated with frequent oral corticosteroids or drugs which inhibit cytochrome 
p450 3A4. HPA axis suppression is frequently unrecognised, such that some patients, 
notably children, only come to light when an adrenal crisis is precipitated by physical stress. 
In order to minimise this risk, ‘higher risk’ patients and those with previously identified 
suppressed cortisol responses to Synacthen testing should undergo an education 
programme to inform them about sick day rules. A review of ICS therapy should also be 
undertaken to ensure that the dose administered is the minimum required to control 
symptoms.  
  
 
Introduction 
Corticosteroids have been established as an important treatment for bronchoconstrictive 
lung disorders ever since the first successful use of cortisone in asthma in 1950.1 The 
subsequent development of inhaled corticosteroid (ICS) preparations in the 1970s2 
revolutionised therapy as it enabled local delivery to the lung in high concentrations and 
limited exposure to other organs. ICS are now firmly established as an important treatment 
  
for chronic asthma and chronic obstructive pulmonary disease.3-6 However, whilst the 
clinical effectiveness of ICS is clear, the development of more potent preparations with 
significant absorption across the lungs has led to recognition of hypothalamic-pituitary-
adrenal (HPA) axis suppression as a clinical challenge. Here, we review the extent of this 
problem, and recommend strategies for its assessment, prevention and treatment.  
 
Mode of action and relative potency 
Five ICS preparations are currently in use in the UK: beclometasone dipropionate (BDP), 
budesonide, ciclesonide, fluticasone propionate and mometasone furoate. These share a 
common mode of action by binding to the glucocorticoid receptor, although preparations 
differ in their pharmacodynamic and pharmacokinetic properties. ICS receptor binding can 
be quantified as relative receptor affinity (RRA) with reference to dexamethasone whose 
affinity is set at 100.7 The RRA of ICS in current use is set out in table 1. Those with the 
highest RRA include fluticasone propionate and mometasone furoate. BDP and ciclesonide 
have lower RRA, but are converted to their active metabolites beclometasone 
monopropionate and desisobutyryl ciclesonide by pulmonary epithelial enzymes. In vitro 
binding of ICS at the glucocorticoid receptor is broadly predictive of in vivo potency, such 
that BDP and budesonide have approximately equal activity, whilst fluticasone is equally 
active at half the microgram dose.3,8 Mometasone is estimated to have equal potency to 
fluticasone whereas ciclesonide has a potency in between BDP and fluticasone.  
 
Factors affecting absorption and systemic concentrations 
Approximately 10 to 60% of ICS administered via a metered dose inhaler enters the lung, 
where it exerts its therapeutic effects. The remainder of the drug is deposited in the 
oropharynx and swallowed. This portion is subsequently absorbed in the gastrointestinal 
tract but undergoes first pass metabolism in the liver by cytochrome p450 3A4 (CYP450 
3A4) and is converted to inactive metabolites. Ciclesonide, fluticasone and mometasone are 
almost completely metabolised, whereas 11% budesonide and 20-40% BDP escapes first 
pass metabolism (table 1).9 Circulating drug concentrations are thus predominantly 
dependent on lung absorption. Although CYP450 3A5 efficiently metabolises glucocorticoids 
in the lungs10, up to 20% of inhaled fluticasone, for example, is still systemically available.11  
 
Systemic side-effects are also affected by plasma protein binding, half-life and systemic 
clearance (table 1). Binding of an ICS to plasma protein (albumin) renders it 
pharmacologically inactive. ICS preparations with high protein binding, such as ciclesonide 
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and its active metabolite desisobutyryl ciclesonide (both >99% bound), may thus be less 
likely to induce cortisol suppression than those with lower protein binding. Preparations with 
short half-lives and high clearance rates may also reduce exposure to the systemic 
circulation. ICS elimination half-lives range from 14 hours for fluticasone to as little as 0.5 
hours for ciclesonide (table 1)12. Metabolism occurs predominantly in the liver with clearance 
rates typically similar to the rate of hepatic blood flow, although systemic clearance of 
desisobutyryl ciclesonide is considerably greater13.   
 
Absorption of ICS also appears to be affected by lung function. Fluticasone absorption is 
higher in healthy subjects than in those with airflow obstruction14, an effect which may be 
less apparent for patients taking budesonide or ciclesonide.15,16 This has clinical relevance 
since the absorption of fluticasone increases with improvement in airflow obstruction, an 
observation that should prompt a dose reduction once asthma is controlled.  
 
Inhibitors of CYP450 3A4 may also affect systemic concentrations of ICS. Reports of 
interactions of itraconazole and ritonavir, both potent inhibitors of CYP450 3A4, with 
budesonide17 or more commonly fluticasone18 confirm the pathological relevance of these 
drug interactions on induction of Cushing’s syndrome and HPA axis suppression. Other 
drugs which act as inhibitors of this enzyme system might be expected to similarly increase 
circulating ICS concentrations (Table 2).19        
 
HPA axis suppression: how common is it? 
Systemic absorption of ICS leads to ACTH suppression and down-regulation of the HPA 
axis, such that the subject’s overall steroid exposure is adjusted to remain within the normal 
range. Whilst clinical signs of Cushing’s syndrome may not be apparent unless high doses 
are administered, even low doses can lead to suppression of the HPA axis. Indeed, the 
relationship between ICS dose and HPA axis suppression is linear, such that no dose is 
completely without risk.20    
 
The prevalence of HPA axis suppression in patients taking ICS is not entirely clear and not 
easy to quantify due to the frequent co-administration of oral corticosteroids in this patient 
group and their potential to suppress the HPA axis in their own right. The prevalence is also 
likely to be affected by ICS potency, dose, treatment duration, delivery method, drug 
interactions and the site of drug activation. In a systematic review and meta-analysis of 732 
adults and children treated with ICS, HPA axis suppression was observed in 6, 7, 10 and 13 
  
percent of patients taking 500, 1000, 1500 and 2000 micrograms/day of fluticasone 
respectively.21 In keeping with its greater potency, fluticasone is the most common ICS 
reported to be associated with HPA axis suppression in children and adults22,23 although an 
important caveat is that this may reflect preferential prescribing at high dose in patients with 
refractory asthma.  
 
Clinical consequences of ICS-induced HPA axis suppression 
The most serious complication of ICS use is adrenal crisis consequent upon suppression of 
the HPA axis and sudden cessation of long-term therapy, or precipitated by trauma, sepsis 
or surgery. However, adrenal crisis appears to occur only rarely after ICS therapy, and 
mainly in children, with one UK survey reporting 33 cases (28 children, 5 adults) from 2912 
questionnaires. As might be anticipated, crisis was more common in patients taking higher 
ICS doses (500-2000 micrograms/day), with the majority taking fluticasone alone (91%) or 
in combination (3%),24 leading the authors to recommend avoidance of doses of fluticasone 
above the licensed dose of 400 micrograms/day in children unless supervised by a 
respiratory physician.    
 
Growth suppression is also an important consideration in children, since ICS are 
recommended for children of all ages with chronic asthma and are likely to be prescribed 
long-term. Severe asthma may itself impair growth but an effect of ICS on growth 
suppression is difficult to prove due to the complex influences of genetic background and 
pubertal factors on height. Some studies have shown short-term growth suppression in 
response to ICS treatment25 but final adult height does not appear to be affected.26 
Childhood is also a critical time for bone development, although the available evidence 
suggests that reduction in bone mineral density (BMD) is not a significant concern with ICS, 
at least at low to moderate doses.27 An adverse effect of ICS use on bone health in adults 
is also unproven, although one study with a 6 year follow-up showed an inverse association 
between cumulative ICS exposure and BMD at both the lumbar spine and femoral neck.28 
Whilst these studies suggest that ICS use may be associated with long-term adverse effects, 
it should be recognised that any such risks are likely to be outweighed by the ability of ICS 
to reduce the need for frequent courses of oral corticosteroids, provided the ICS dose is 
carefully regulated.3      
 
How should patients with ICS-induced HPA axis suppression be managed? 
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Since clinically relevant HPA axis suppression in patients taking ICS is generally confined 
to patients exposed to higher cumulative doses, universal screening is neither practical nor 
justified. We recommend that a case-finding approach be considered such that patients with 
specific risk factors for HPA axis suppression, signs of Cushing’s syndrome or symptoms of 
adrenal insufficiency be offered testing. Such risk factors would include patients exposed to 
high cumulative doses of ICS, patients taking more than 800 micrograms/day BDP 
equivalent, patients with a history of frequent oral corticosteroid therapy for exacerbations, 
and those receiving concomitant drug therapy with an agent which inhibits CYP450 3A4 
(figure 1). A presentation with shock, hypoglycaemia29 or reduced consciousness in a child 
with a history of high dose ICS exposure should also prompt investigation, as should a 
presentation with slowed growth. We anticipate that such patients are likely to concentrate 
in secondary care respiratory clinics, as these are often the patients with the most refractory 
disease.  
 
One of two potential approaches to management might then be considered. Advocates of 
endocrine testing would favour a management approach based on biochemical assessment 
of endogenous cortisol production, which would be required to establish suppression of the 
HPA axis with diagnostic certainty. A number of endocrine tests might be considered in this 
context but a reasonable first step would be measurement of an early morning (08:00 a.m) 
cortisol. This test has high specificity if a low cut-off value (<100 nmol/l) is used. However, 
sensitivity is poor, and a value within the laboratory reference range does not rule out the 
presence of adrenal suppression. A dynamic test is required in these circumstances to 
confirm the integrity or otherwise of the HPA axis. If a testing strategy is to be followed, we 
would advocate the use of the standard dose (250 micrograms) ACTH (Synacthen) test in 
adults since data on normative responses are now available for all commonly used cortisol 
assays in the UK.30 Assay interference does not appear to be a concern,31 and false negative 
results are uncommon provided the usual caveats of interference with oestrogen therapy30 
or recent onset axis suppression are recognised. In a recent retrospective analysis of a large 
cohort of patients on ICS who had undergone standard dose Synacthen testing, Woods et 
al found that a basal cortisol of >348 nmol/l was 100% specific for a ‘pass’ to Synacthen 
testing whereas a basal cortisol value of <34 nmol/l gave 100% sensitivity for failure.32 The 
authors estimated that up to 50% of Synacthen tests might thus be avoided by adopting 
these basal cortisol cut-offs. In children, the low dose Synacthen test is used in preference 
by many centres, although considerable variation exists with respect to the dose 
administered (complicated by the need for dilution), sample timing and diagnostic criteria 
  
applied.33 Supporters of the low dose test believe that it detects subtle degrees of adrenal 
insufficiency otherwise missed by the standard dose test, whereas critics argue that this 
increased sensitivity generates false positive results. A major limitation is the inadequate 
normative data available for interpretation; centres should be encouraged to develop age- 
and gender-appropriate reference ranges if they are going to rely on this test for 
investigation. Other approaches for diagnosis which might avoid dynamic testing have also 
been considered, including morning ACTH34 and salivary cortisone levels,35 although further 
studies are needed before these can be considered as potential alternatives, whether for 
diagnosis or in the assessment of axis recovery.          
 
The clinical consequences, however, of often minor reductions in serum cortisol response 
to Synacthen in patients established on ICS are not currently known, and the benefits and 
potential disadvantages of a systematic biochemical testing policy, especially with respect 
to treatment adherence, remain to be established. Until such data become available, a 
pragmatic alternative approach could be considered, whereby ‘higher risk’ patients (figure 
1) are presumed to have some degree of HPA axis suppression, and widespread, resource-
intensive endocrine testing is avoided. Management should then focus on: (1) careful patient 
education about the need for steroid supplementation at times of stress (daily oral steroids 
may not be necessary as overall glucocorticoid exposure is already high), and (2) a review 
of the ICS preparation and dose (figure 1). These overriding principles would also apply to 
any patients who have already undergone biochemical testing and been found to have 
subnormal dynamic test responses.   
 
As with other causes of adrenal insufficiency,36, 37 an education programme should train 
patients in recognising stressful situations (e.g. infection, trauma or surgery) and the 
importance of additional steroid supplementation at these times to reduce the risk of adrenal 
crisis. Patients should be provided with specific written advice about steroid replacement in 
the event of a severe intercurrent illness or surgery.3, 36, 37 For minor physical stress, a daily 
oral hydrocortisone dose of 40mg in adults or 20-30 mg/m2 in children is appropriate, 
increasing to higher intravenous doses in cases of severe physical stress or 
diarrhoea/vomiting (figure 1).36, 37 Patients should also be encouraged to carry a steroid 
emergency card to include details on their ICS preparation, and the respiratory physician 
and endocrinologist responsible for their care. Adoption of the new Pan-European 
emergency card should be encouraged wherever possible.38 Patients may also wish to 
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consider wearing Medic-Alert jewellery and they should be supplied with a glucocorticoid 
emergency kit.  
 
Since ICS-induced HPA axis suppression is potentially reversible, clinicians should review 
the potency and dose of ICS therapy, in parallel with embarking upon a patient education 
programme. The minimum ICS dose to control symptoms should be used and therapy 
should be ‘stepped down’ once asthma is controlled.3 This is an important consideration but 
is frequently overlooked, leaving patients at risk of over-treatment. A slow reduction, 
comprising a 25-50% reduction in ICS dose every three months, is appropriate3,39 since 
some patients may deteriorate rapidly. For this reason, dose reductions and/or change in 
ICS preparation should always be supervised by the respiratory team. Spacer devices may 
also be useful in increasing airway deposition and reducing oropharyngeal exposure. 
Concomitant use of fluticasone and ritonavir should be avoided; if ritonavir is needed then 
this should be used in combination with another ICS such as low dose budesonide or BDP.   
 
In patients who have undergone biochemical testing, recovery of the HPA axis should be 
tested for with a repeat Synacthen test 3 months after any ICS dose reduction, recognising 
that recovery may take many months, or, in patients treated with high doses of ICS and/or 
oral doses for a long period of time, not occur at all. In such circumstances, patients may 
require lifelong glucocorticoid replacement therapy.  
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Figure 1. Recommendations for management of ICS-induced HPA axis suppression 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 Patients with a Cushingoid appearance  Patients with persistent symptoms of adrenal insufficiency*  High dose ICS therapy for >3 months (≥ 400 µg/day 
fluticasone or mometasone, ≥800 µg/day budesonide, BDP 
or ciclesonide)  Concomitant therapy with potent CYP450 3A4 inhibitors 
(table 2)  Oral corticosteroids for >2 consecutive weeks or >3 
Higher risk patients 
Management  Patient and family education 
o Steroid emergency card  
o Medic-Alert jewellery 
o Access to emergency hydrocortisone injection and phone number for medical advice  Provide specific written advice about stress dose of steroids to cover illness∫ or surgery῀  Review ICS preparation in consultation with a respiratory physician. Reduce dose and/or change to less potent preparation if disease 
control good. Maintain on lowest dose of ICS which keeps disease controlled.   In children, monitor growth on an annual basis.  
* Emergency management may be required for symptoms of adrenal crisis such as hypoglycaemia or hypotension. 
∫ In adults, cover illness or fever with 20mg bd oral hydrocortisone. In children, use 20-30 mg/m2/day oral hydrocortisone in three or four divided doses. Parenteral doses may be 
needed in cases of diarrhoea/vomiting.37 
῀ For detail, see reference 37. In adults, cover major surgery with 100mg IV hydrocortisone injection followed by 50mg qds IV hydrocortisone or 200mg IV infusion over first 24 
hours37. In children, use 50-mg/m2 IV, followed by 50-100 mg/m2/day IV divided in 6-hourly doses.37    
If patients have undergone endocrine testing:  9am cortisol<100 nmol/l: suggestive of HPA axis 
suppression. Confirm with Synacthen test.   9am cortisol 100-350 nmol/l: indeterminate. 
Synacthen test needed.   9am cortisol >350 nmol/l: normal. 
 
HPA axis suppression confirmed 
  
Table 1. Pharmacodynamic and pharmacokinetic properties of inhaled corticosteroids (adapted from 7 and 10).  
 
Corticosteroid 
                                                                                                                      
Relative receptor 
affinitya
Protein binding 
(%)
Oral bioavailability 
(%) 
Systemic 
clearance (L/h) 
Half-life (h) 
Beclomethasone 
dipropionate/17-
monopropionateb 
53/1345 87 20/40 150/120 UK/2.7 
Budesonide 935 88 11 84 2.0 
Ciclesonide/desisobutyryl 
ciclesonideb 
12/1200 
 
99/99 <1/<1 152/228 0.5/4.8 
Fluticasone propionate 1800 90 1 66 14.4 
Mometasone furoate 2200 99 <1 53 UK 
a Relative receptor binding affinities are expressed with reference to dexamethasone whose affinity is set at 100 
b Beclomethasone dipropionate and ciclesonide are prodrugs which are activated in the lungs to their active metabolites, beclomethasone 17-
monopropionate and desisobutyryl ciclesonide respectively.  
UK, unknown.  
 
 
 
 
Table 2. Inhibitors of cytochrome p450 3A4 
 
 
 
 
 
 
Strong inhibitors Moderate inhibitors 
 
Ritonavir 
Indinavir 
Nelfinavir 
Saquinavir 
Clarithromycin 
Chloramphenicol 
Verapamil 
Diltiazem 
Aprepitant 
Erythromycin 
Fluconazole 
Bergamottin (in grapefruit juice) 
Itraconazole 
Ketoconazole 
Nefazodone 
 
